Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Smith & Nephew appoints Ajay Dhankhar as chief corporate development & strategy officer

(Sharecast News) - Medical technology company Smith & Nephew said on Monday that it has appointed Ajay Dhankhar as chief corporate development & strategy officer with immediate effect. It said that as both a senior management consultant and investment banker, Dhankhar has advised CEOs and boards at some of the world's leading healthcare companies, helping deliver "substantial shareholder value".

His experience includes 25 years with McKinsey & Company where he was a senior partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy and M&A for Life Sciences and Global Head of Life Sciences R&D.

Following that, Dhankhar served as a managing director in the financial advisory healthcare group of Lazard, where he was the Global Head of Medical Technology, Diagnostics and Tools.

More recently, he founded and led Bluish Capital, a strategy and financial advisory firm focused on deploying growth capital to support high quality, recently FDA approved assets.

Chief executive Deepak Nath said: "Ajay's unique blend of scientific rigor, strategic insight, business development, integrations, and operational excellence, combined with his entrepreneurial leadership style, makes him exceptionally well-suited to help shape our future. We are pleased to have him join our leadership team at this exciting time for the company."

Share this article

Related Sharecast Articles

Ibstock earnings dip as expected in 'progressively tougher market'
(Sharecast News) - Building products manufacturer Ibstock reported a drop in full-year earnings on Thursday, in line with revised guidance, in a "progressively tougher market".
OSB hikes dividend, launches buyback after fall in profit
(Sharecast News) - OSB Group reported a decline in annual profit for 2025 on Thursday as higher administrative costs and an impairment charge weighed on earnings, though the specialist lender said loan growth and originations increased and it announced a £100m share buyback alongside a higher dividend.
Spire Healthcare grows annual profits, but NHS outlook uncertain in 2026
(Sharecast News) - Takeover target and Spire Healthcare reported a small rise in adjusted profits over 2025 which it hailed as a "resilient performance" against a backdrop of significant cost headwinds, though the outlook for 2026 was proving more uncertain due to a drop in NHS commissioning activity.
Bloomsbury shares spark on 2027 profit outlook
(Sharecast News) - Shares in Bloomsbury Publishing shot higher on Thursday after it said profit for the year ending 28 February 2027 was set to be "materially ahead" of market expectations as Sarah J. Maas will publish her next two novels within the next year.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.